Abstract
The integration of multimodal contrast-enhanced diagnostic imaging techniques with noninvasive high-intensity focused ultrasound (HIFU) synergistic therapy could allow the real-time guidance, monitoring, and assessment of cancer therapeutic procedures and effects. Herein, we investigated the use of folate-targeted perfluorohexane nanoparticles carrying bismuth sulfide (Bi2S3) (FLBS-PFH-NPs) as a dual-modal contrast agent for ultrasound/computed tomography (US/CT) imaging and aimed to targeted increase the therapeutic efficiency of HIFU for cervical cancer treatment. FLBS-PFH-NPs were fabricated to investigate their potential as theranostic nanoplatforms. Their characteristics, phase-transformation properties, and cytotoxicities were also studied in this work. Sequential modifications with polyethylene glycol (PEG) endowed the FLBS-PFH-NPs with excellent stability and good biocompatibility. Moreover, compared with a non-folate-targeted group, the experimental group that received folate ligands had higher internalization efficiency and specificity. We sequentially investigated the effectiveness of these nanoparticles when used as dual-modal contrast agents in US and CT imaging in vitro and in vivo. The capsulated PFH could undergo a phase transition and form microbubbles upon ultrasonic irradiation, which enhanced the cavitation effects of HIFU in the targeted regions. Then, they were applied to in vitro bovine liver samples; the composite nanoparticles improved the efficiency of HIFU synergistic ablation. Our in vivo results also revealed that the coagulative necrosis volumes of tumors in the folate-targeted groups with HIFU ablation after FLBS-PFH-NP administration were significantly greater than those of the non-folate-targeted groups. Pathological and immunohistochemical examinations were systematically performed to further verify these results. In brief, FLBS-PFH-NPs may serve as a dual-modal contrast agent to enhance US/CT imaging and HIFU synergistic therapy. Novel nanosized multifunctional contrast agents would be of great value and could provide more comprehensive diagnostic information for more accurate and effective cancer therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
